Tesamorelin vs CJC-1295: Choosing the Right GH Peptide

Two GH Peptides, Two Different Profiles

Both Tesamorelin and CJC-1295 stimulate growth hormone release through the GHRH pathway. Both are synthetic analogues of natural GHRH. And both are used to combat the effects of age-related GH decline. But they were developed for different purposes, have different clinical evidence profiles, and suit different patient goals.

Understanding the distinction helps you choose the right peptide — or combination — for your specific objectives.

Tesamorelin: The FDA-Approved Specialist

Tesamorelin (brand name Egrifta) is a synthetic analogue of GHRH consisting of all 44 amino acids of natural GHRH with a trans-3-hexenoic acid modification at the N-terminus. It was developed by Theratechnologies and received FDA approval in 2010 for the treatment of HIV-associated lipodystrophy — the abnormal accumulation of visceral fat in HIV patients on antiretroviral therapy.

This makes Tesamorelin unique: it is the only growth hormone releasing peptide with FDA approval for any indication.

Visceral Fat Reduction: The Clinical Evidence

Tesamorelin's headline claim is visceral fat reduction, and the data is compelling:

Phase III Trials (Falutz et al., 2007; 2008):

• 816 HIV-positive patients with excess abdominal fat
• 2 mg Tesamorelin daily via subcutaneous injection for 26 weeks
• Results: 15–18% reduction in visceral adipose tissue (measured by CT scan)
• Maintained with continued treatment; visceral fat returned after discontinuation
• Significant reduction in trunk fat and waist circumference
• Improved triglycerides and cholesterol ratios

Key lipid improvements:

• Triglycerides decreased by 50+ mg/dL in responders
• Total cholesterol:HDL ratio improved
• Non-HDL cholesterol decreased

Cognitive benefits (HATNU study): A 2017 study by Stanley et al. in Neurology found that Tesamorelin improved cognitive function in HIV patients, potentially through IGF-1's neurotrophic effects. Executive function, processing speed, and memory showed measurable improvements.

Tesamorelin's Mechanism

Tesamorelin binds to GHRH receptors on the anterior pituitary with high affinity, stimulating GH synthesis and secretion. The trans-3-hexenoic acid modification provides:

• Resistance to enzymatic degradation (longer activity than natural GHRH)
• Preserved biological activity identical to native GHRH
• Consistent, predictable GH release kinetics

CJC-1295: The Versatile Anti-Aging Peptide

CJC-1295 (modified GRF 1-29, no DAC) is a truncated GHRH analogue consisting of the first 29 amino acids with four amino acid substitutions to improve stability. While it lacks FDA approval, it has a broader profile for general anti-aging and wellness applications.

CJC-1295's Broader Benefits

CJC-1295 (especially when paired with Ipamorelin) has documented benefits across multiple systems:

• Sleep: Significant improvement in deep/delta sleep quality (often the first benefit reported)
• Body composition: Both fat loss and lean muscle gain
• Recovery: Faster healing from exercise and injury
• Skin quality: Improved collagen synthesis, thickness, and hydration
• Cognitive function: Enhanced clarity and mood
• Immune function: Improved infection resistance

Head-to-Head Comparison

Feature	Tesamorelin	CJC-1295 (no DAC)
FDA approved	Yes (HIV lipodystrophy)	No
Amino acid length	44 AA (full GHRH)	29 AA (truncated GHRH)
Primary evidence	Visceral fat reduction (Phase III)	General anti-aging (clinical + anecdotal)
Visceral fat reduction	15–18% (CT-verified)	Moderate (less robust data)
Sleep improvement	Moderate	Significant (esp. with Ipamorelin)
Lean muscle building	Moderate	Moderate–significant (with Ipamorelin)
Cognitive data	Yes (HATNU study)	Limited
Lipid improvement	Yes (triglycerides, cholesterol)	Some evidence
Best paired with	Ipamorelin	Ipamorelin
Dosing frequency	Daily (2 mg)	Daily (100–300 mcg)
Typical cycle length	12–26 weeks	8–12 weeks
Cost per month	Higher	Lower

When to Choose Tesamorelin

Tesamorelin is the better choice when:

• Visceral fat reduction is the primary goal. No other GH peptide has Phase III clinical trial data showing 15–18% visceral fat reduction verified by CT imaging.
• You want FDA-approved evidence. For those who prioritise regulatory validation, Tesamorelin stands alone.
• Lipid optimisation is important. The triglyceride and cholesterol improvements are well-documented.
• Cognitive enhancement in the context of metabolic dysfunction. The HATNU study data suggests particular benefit for executive function.

Tesamorelin Protocol

• Dose: 1–2 mg subcutaneous daily
• Timing: Before bed on empty stomach
• Cycle: 12–26 weeks (effects reverse gradually after discontinuation)
• Pairing: Can be combined with Ipamorelin for amplified GH release

When to Choose CJC-1295 + Ipamorelin

CJC-1295 (with Ipamorelin) is the better choice when:

• General anti-aging is the goal. Sleep, recovery, body composition, skin quality, and energy all improve.
• Sleep improvement is a priority. The CJC-1295 + Ipamorelin combination consistently produces the most dramatic sleep improvements.
• You want a more flexible, cost-effective protocol. CJC-1295 is significantly less expensive per month and can be cycled more flexibly.
• You are building a broader peptide stack. CJC-1295 + Ipamorelin integrates easily with BPC-157, TB-500, and other peptides.

CJC-1295 + Ipamorelin Protocol

• Dose: CJC-1295 100–300 mcg + Ipamorelin 100–300 mcg combined
• Timing: Before bed on empty stomach
• Cycle: 8–12 weeks on, 4 weeks off
• Frequency: Daily or 5 on/2 off

Can You Use Both?

Yes. Some advanced protocols use Tesamorelin for targeted visceral fat reduction combined with Ipamorelin for selective GH amplification. This provides the visceral fat data of Tesamorelin with the pulsatile GH release benefits of Ipamorelin.

At Mito Labs, both Tesamorelin and CJC-1295 + Ipamorelin are available as part of our GH peptide range. Our clinical team can help determine which approach aligns best with your biomarkers and goals.

The Bottom Line

There is no "better" peptide — only the right peptide for your specific situation. Tesamorelin wins on FDA approval and visceral fat data. CJC-1295 + Ipamorelin wins on versatility, sleep improvement, and cost-effectiveness. Both work through the GHRH pathway, both are well-tolerated, and both restore what aging takes away: robust, pulsatile growth hormone secretion.

Mito Labs provides pharmaceutical-grade Tesamorelin and CJC-1295 + Ipamorelin, each with full certificates of analysis. Consult our team to design the right protocol for you.